TIDMFUM

RNS Number : 2556J

Futura Medical PLC

03 December 2018

Futura Medical plc

("Futura" or "the Company")

Total Voting Rights

3 December 2018

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology announces that, for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 204,583,439 Ordinary Shares.

Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is 204,583,439 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 
  For further information please          For media enquiries please contact: 
   contact: 
 
 Futura Medical plc                      Optimum Strategic Communications 
 Angela Hildreth, FD/COO                 Mary Clark/ Hollie Vile/ Ellie 
                                          Blackwell 
 investor.relations@futuramedical.com    Email: futuramedical@optimumcomms.com 
 www.futuramedical.com                   Tel: +44 (0) 203 950 9144 
 Tel: +44 (0) 1483 685 670 
 
 Nominated Advisor/Broker 
 N+1 Singer 
  Aubrey Powell/ Ben Farrow (Corporate 
   Finance) 
  Tom Salvesen/ Mia Gardner (Corporate 
   Broking) 
 Tel: +44 (0) 20 7496 3000

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys(R) drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVRKMMGZZFNGRZM

(END) Dow Jones Newswires

December 03, 2018 08:00 ET (13:00 GMT)

Futura Medical (LSE:FUM)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Futura Medical Charts.
Futura Medical (LSE:FUM)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Futura Medical Charts.